Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: A randomized controlled trial

Journal of Hypertension

Volumn 29, Issue 8, 2011, Pages 1649-1659

  Matsuzaki, Masunori ^a   Ogihara, Toshio ^b   Umemoto, Seiji ^a   Rakugi, Hiromi ^b   Matsuoka, Hiroaki ^c   Shimada, Kazuyuki ^d   Abe, Keishi ^e   Suzuki, Norihiro ^f   Eto, Tanenao ^g   Higaki, Jitsuo ^h   Ito, Sadayoshi ⁱ   Kamiya, Akira ^a   Kikuchi, Kenjiro ^j   Suzuki, Hiromichi ^k   Tei, Chuwa ^l   Ohashi, Yasuo ^l   Saruta, Takao ^f  

^a YAMAGUCHI UNIVERSITY   (Japan)

^b DOKKYO MEDICAL UNIVERSITY   (Japan)

^c JICHI MEDICAL UNIVERSITY   (Japan)

^d Japan Community Healthcare Organization Sendai Hospital   (Japan)

^e KEIO UNIVERSITY   (Japan)

^f UNIVERSITY OF MIYAZAKI   (Japan)

^g EHIME UNIVERSITY   (Japan)

^h TOHOKU UNIVERSITY   (Japan)

ⁱ ASAHIKAWA MEDICAL COLLEGE   (Japan)

^j SAITAMA MEDICAL UNIVERSITY   (Japan)

^k KAGOSHIMA UNIVERSITY   (Japan)

^l UNIVERSITY OF TOKYO   (Japan)

more..

Author keywords

adrenergic antagonists; angiotensin antagonists; antihypertensive therapy diuretics; calcium channel blockers; clinical trials; combination; drug therapy

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENIDIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INDAPAMIDE; IRBESARTAN; LOSARTAN; OLMESARTAN; TELMISARTAN; THIAZIDE DIURETIC AGENT; TRICHLORMETHIAZIDE; VALSARTAN;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DRUG EFFICACY; FEMALE; HAZARD RATIO; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SECONDARY ANALYSIS; STROKE; TREATMENT OUTCOME;

EID: 79960591166     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328348345d     Document Type: Article

References (27)

1. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996; 275:1571-1576. (Pubitemid 26154243)
2. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 2003; 21:1055-1076. (Pubitemid 36667856)
3. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369:201-207. (Pubitemid 46111014)
4. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366:1545-1553. (Pubitemid 41540112)
5. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial.HOT Study Group. Lancet 1998; 351:1755-1762. (Pubitemid 28269185)
6. Koshy S, Bakris GL. Therapeutic approaches to achieve desired blood pressure goals: focus on calcium channel blockers. Cardiovasc Drugs Ther 2000; 14:295-301. (Pubitemid 30447231)
7. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42:1206-1252. (Pubitemid 37553153)
8. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21:1011-1053.
9. Japanese Society of Hypertension. Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2004). Hypertens Res 2006; 29 (Suppl):S1-S105.
10. Yamamoto Y, Sonoyama K, Matsubara K, Furuse M, Yatsuhashi T, Hamada T, et al. The status of hypertension management in Japan in 2000. Hypertens Res 2002; 25:717-725. (Pubitemid 35153760)
11. Costanzo P, Perrone-Filardi P, Petretta M, Marciano C, Vassallo E, Gargiulo P, et al. Calcium channel blockers and cardiovascular outcomes: a metaanalysis of 175 634 patients. J Hypertens 2009; 27:1136-1151.
12. Levi F, Lucchini F, Negri E, La Vecchia C. Trends in mortality from cardiovascular and cerebrovascular diseases in Europe and other areas of the world. Heart 2002; 88:119-124. (Pubitemid 34787755)
13. Japanese Society of Hypertension Guidelines Subcommittee for the Management of Hypertension. Guidelines for the management of hypertension for general practitioners. Hypertens Res 2001; 24:613-634.
14. Yao K, Nagashima K, Miki H. Pharmacological, pharmacokinetic, and clinical properties of benidipine hydrochloride, a novel, long-acting calcium channel blocker. J Pharmacol Sci 2006; 100:243-261.
15. Ogihara T, Matsuzaki M, Matsuoka H, Shimamoto K, Shimada K, Rakugi H, et al. The Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) trial: rationale and design. Hypertens Res 2005; 28:331-338. (Pubitemid 40895055)
16. National Intervention Cooperative Study in Elderly Hypertensives Study Group. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. National Intervention Cooperative Study in Elderly Hypertensives Study Group. Hypertension 1999; 34:1129-1133.
17. The GLANT Study Group. A 12-month comparison of ACE inhibitor and CA antagonist therapy in mild to moderate essential hypertension: the GLANT Study. Study Group on Long-term Antihypertensive Therapy. Hypertens Res 1995; 18:235-244.
18. Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359:2417-2428.
19. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-2997.
20. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003. (Pubitemid 34286536)
21. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA): a multicentre randomised controlled trial. Lancet 2005; 366:895-906. (Pubitemid 41265663)
22. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363:2022-2031. (Pubitemid 38781102)
23. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27:2121-2158.
24. Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palu C, et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002; 106: 2422-2427. (Pubitemid 35278796)
25. Ogihara T, Nakao K, Fukui T, Fukiyama K, Ueshima K,Oba K, et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension 2008; 51:393-398. (Pubitemid 351159955)
26. Ogihara T, Saruta T, Rakugi H, Matsuoka H, Shimamoto K, Shimada K, et al. Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. Hypertension 2010; 56:196-202.
27. Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A. The Felodipine Event Reduction (FEVER) study: a randomized long-term placebocontrolled trial in Chinese hypertensive patients. J Hypertens 2005; 23:2157-2172. (Pubitemid 41666745)